Abstract | PURPOSE: METHODS:
Combretastatin was incorporated into liposomes with surfaces modified by the addition of cyclo(Arg-Gly-Asp-D-Phe-Cys) (RGD) to create an immunoliposome (IL). This addition of RGD allows the liposome to be preferentially targeted to alphavbeta3, an integrin up-regulated in the vasculature of irradiated tumors. C57BL mice bearing a transplanted B16-F10 melanoma were randomly assigned to one of the following treatment groups: untreated, a single dose of 5-Gy radiation (IR), IL (14.5 mg/kg of combretastatin), 5-Gy radiation plus IL, and a systemic administration of free drug (81.0 mg/kg of combretastatin). RESULTS: In this transplanted tumor model, there was no significant increase in the volume of the IL + IR (5 Gy) treated tumors during the initial 6 days posttreatment; all other treatment groups exhibited exponential growth curves after day 3. The IL + IR (5 Gy) treatment resulted in a 5.1-day tumor growth delay compared to untreated controls. CONCLUSIONS: These findings indicate that preferential targeting of antivascular drugs to irradiated tumors results in significant tumor growth delay.
|
Authors | Christopher B Pattillo, Farid Sari-Sarraf, Ramakrishna Nallamothu, Bob M Moore, George C Wood, Mohammad F Kiani |
Journal | Pharmaceutical research
(Pharm Res)
Vol. 22
Issue 7
Pg. 1117-20
(Jul 2005)
ISSN: 0724-8741 [Print] United States |
PMID | 16028012
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Angiogenesis Inhibitors
- Antineoplastic Agents, Phytogenic
- Bibenzyls
- Liposomes
- Stilbenes
- combretastatin
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage)
- Animals
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Bibenzyls
(administration & dosage)
- Combined Modality Therapy
- Drug Delivery Systems
- Liposomes
- Melanoma, Experimental
(drug therapy, pathology, radiotherapy)
- Mice
- Mice, Inbred C57BL
- Neoplasm Transplantation
- Stilbenes
(administration & dosage)
- Tumor Burden
|